AVBP vs EVRG · $1.39B cap vs P/E 22, rev $5.96B
ArriVent BioPharma, Inc. Common Stock (AVBP) versus Evergy, Inc. (EVRG) — a side-by-side from cached financials, not a winner call.
ArriVent BioPharma, Inc. Common Stock (AVBP) is a biotechnology company listed on US.
Evergy, Inc. (EVRG) is a utilities - regulated electric company listed on NASDAQ.
AVBP does not have a complete income-statement cache yet.
Latest reported EVRG revenue for 2025-12-31 was $5.96B. Net income was $855.6M. Revenue was up 2.0% from 2024-12-31 to 2025-12-31. EVRG currently screens at market cap $19.10B and trailing P/E 22.0.
AVBP currently screens at market cap $1.39B. EVRG currently screens at market cap $19.10B and trailing P/E 22.0.
Not investment advice. Open the AVBP and EVRG stock pages for the full models.
Not investment advice.